|Articles|September 22, 2016

EpiPen Controversy: Mylan CEO Faces Congressional Committee

September 22, 2016

Mylan CEO Heather Bresch appeared before the House Committee on Oversight and Government Reform on Sept. 21, 2016 to explain the company’s decision to increase the price of EpiPen more than 400%. The meeting comes after multiple members of Congress raised concerns about the price of the life-saving drug, which is used to treat anaphylaxis.

In her pre-released testimony, Bresch attempted to clarify exactly how much money Mylan makes off each EpiPen sale.

For the rest of this news release, see Pharmaceutical Technology.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

EpiPen Controversy: Mylan CEO Faces Congressional Committee

Newsletter

Related Content

Can AI Help Solve the Issue of High Failure Rates in Clinical Trials?

How is AI Supporting Clinical Trial Design?

The Real Value Equation: How Humans and AI Create and Destroy Value in Pharma

Data Quality in Drug Development: The Missing Foundation to Realize AI’s Promise in Clinical Trials

From Ambition to Advantage: How Life Sciences Leaders Are Scaling AI

Trending on PharmExec

Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade

Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences

FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices

Taming the Complexity of CGT Commercialization: 5 Keys to a Workable Operating Model

GSK Enters Multi-Year Collaboration with Helix to Develop Precision Medications